Ebola virus- outbreak of the disease

Modified Vectored vaccines

MVA-BN-Filo, a vaccine which encode the glycoprotein form the Ebola virus and Sudan Virus as well as from the Marburg and Nipah Virus. This vaccine exposed the capability to induce the humoral and cellular immune response indulging antibodies.

Human Adenovirus vectored vaccines

According to WHO, human adenovirus vector or Ad26 vector was first clinical trialed with MVA-BN-Filo as intervals for 8 weeks. There has been less attention to clinical trial vaccines in Sudan and west African outbreak for Ad26 vector, which is a heterologous parallel to MVA-BN-Filo has commenced.